Resident @MSK_RadOnc @pike_lab ☢️ | MD-PhD @DrexelMedicine @FoxChaseCancer 🩺
New York, USA
Joined September 2019
- Tweets1.5K
- Following1.8K
- Followers792
- Likes6.7K
Pinned Tweet
We made the cover of this @CR_AACR issue!!! 🥳🥳🥳
Published Paper: aacrjournals.org/cancerres/a…
Rascore Website: dunbrack.fccc.edu/rascore/
@RolandDunbrack @DrexelMcbg @FCCCAcademics
Mitchell Parker, MD, PhD retweeted
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine
Mitchell Parker, MD, PhD retweeted
Fantastic work led by @dtbergman analyzing 3,893 patients treated with Linac SRS for brain mets. OS plateaus from 5-20 lesions & salvage WBRT is rare. Data support an SRS-first strategy over fixed lesion limits! doi.org/10.1093/noajnl/vdag2… @MSKCancerCenter @MSK_RadOnc
Mitchell Parker, MD, PhD retweeted
Proud of work co-led by Emily Miao & Emily Wo uniting 11 centers for the largest cohort of tx-naive EGFR+ NSCLC brain mets. Genomic subtype drives CNS outcomes: L858R & atypical mutations benefit most from upfront SRS. sciencedirect.com/science/ar… @MSKCancerCenter @MSK_RadOnc
Mitchell Parker, MD, PhD retweeted
Exciting work from our own Dr. David Billing, lead author of a new study in @Nature!
The team identifies a critical DNA repair pathway that maintains oncogene-carrying ecDNA, revealing a potential therapeutic vulnerability in aggressive cancers.
nature.com/articles/s41586-0…
Mitchell Parker, MD, PhD retweeted
Excited to share our new paper with @Mitch_P and @Luke_Pike_MD @pike_lab!
Nearly 4,000 brain mets patients treated with linac-based SRS at MSK: contemporary survival outcomes, prognostic factors, and what happens next with salvage treatment. 🧵
doi.org/10.1093/noajnl/vdag2…
Mitchell Parker, MD, PhD retweeted
Coming up at #ASTRO26: MSK radiation oncologist @brandon_imber will present research on bridging radiotherapy and systemic inflammation before CAR T-cell therapy for B-cell lymphomas.
🗓️ Wednesday, September 30 | 9:15 a.m. ET
Learn more: bit.ly/3VCyz4K
Mitchell Parker, MD, PhD retweeted
Stellar @MSK_RadOnc / @MSKCancerCenter Resident @Elisa_Liu_ will present on Renal Cell Spinal metastases treated with SBRT this morning at 10:15AM at @ASTRO_org 2026.
@DanHigginsonMD @MattMcMillanMD.
sciencedirect.com/science/ar…
Mitchell Parker, MD, PhD retweeted
Med Student Spotlight:
@Zach_Yazdani is an MS3 with an oral presentation on a deep learning pathology model to predict outcomes in patients with brain metastases #ASTRO2026
Mitchell Parker, MD, PhD retweeted
Today at #ASTRO26: MSK radiation oncologist @alexgoglia will present five-year outcomes from a trial of MR-guided SBRT with a focal DIL boost for intermediate-risk prostate cancer.
🗓️ Monday, September 28 | 3:10 p.m. ET
Learn more: bit.ly/47lXHPT
Mitchell Parker, MD, PhD retweeted
Thrilled about this joint initiative with the @AnthropicAI team!
We’re hiring for a few roles (eng, MD, partnerships) focused on these efforts. We look for extremely driven individuals that understand how transformative this tech can be and want to have an outsized, positive impact on the world.
Please reach out if you think you fit the profile for any of the aforementioned roles!
"Access to medical knowledge shouldn't depend on geography," said Daniel Nadler, founder and CEO of OpenEvidence.
That's why OpenEvidence and @AnthropicAI are bringing a specialized version of OpenEvidence, free, to clinicians in about 100 low- and middle-income countries, including Uganda, Angola, Sudan, Haiti, and Mongolia. More here: reuters.com/legal/litigation…
Mitchell Parker, MD, PhD retweeted
Our newest publication on proton hypofractionated spine radiotherapy for spinal metastases is in press in the @IJROBP. @DanHigginsonMD @SpineOncDoc @OriBarzilai.
tl;dr: Proton hypofractionated RT for spinal metastases looks feasible and effective (1 y local failure rate 10% in acohort where 81% of patients had prior overlapping RT). Coverage (CTV D95% biological effective dose) is associated with risk of local failure. Extra caution is warranted when a 3rd or 4th overlapping course is being done.
sciencedirect.com/science/ar…
Mitchell Parker, MD, PhD retweeted
The Pike Lab at @MSK_RadOnc has 13 abstracts at the upcoming @ASTRO_org 2026 AGM. Come check out how we are advancing the management of brain metastases.
Mitchell Parker, MD, PhD retweeted
Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter.
“AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK.
Full press release:
mskcc.org/news-releases/mskc…
Mitchell Parker, MD, PhD retweeted
Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence have partnered to bring cutting-edge AI and precision oncology expertise closer to the point of care. By integrating OpenEvidence into MSK's Epic workflow and embedding MSK's @OncoKB™ precision oncology knowledge base directly into OpenEvidence, clinicians can access trusted, evidence-based insights within their existing clinical workflows.
“We're excited that OpenEvidence will widen OncoKB's reach, bringing MSK's expert interpretation of a patient's unique cancer genetics to cancer care providers across the U.S. to help them make molecularly informed treatment decisions,” says Dr. Debyani Chakravarty (@CDebyaniPhD), a lead scientist for OncoKB at MSK.
Learn more about this new collaboration: bit.ly/4AiLZTt
Mitchell Parker, MD, PhD retweeted
🚨 We’re hiring at MSK!
🎯 Director, Metastatic Disease Team
👥 Lead ~20 faculty
🧪 Drive innovative trials
🔬 ~50% research time (track-dependent)
🌐 Shape care across @MSKCancerCenter
Help define what’s next in @MSK_RadOnc. 🚀
Contact @seanmmcbride if interested.
Click here for more details: msk.wd108.myworkdayjobs.com/…
Mitchell Parker, MD, PhD retweeted
Attending #ASTRO26? Join MSK Radiation Oncology leadership & residents for coffee, donuts & informal networking! ☕🍩
📅 Sept 28, 10-11 AM 📍 Exhibit Hall, Booth #2840
👉 Register here: forms.cloud.microsoft/r/6UuK…
#RadOnc #MedEd #Residency #ASTRO2026
Mitchell Parker, MD, PhD retweeted
Verified U.S. clinicians can get free GPT-6 Astra (Pro) access today via ChatGPT for Clinicians.
Sign up: chatgpt.com/plans/clinicians…
Mitchell Parker, MD, PhD retweeted
It’s 2026, and millions of patients still carry CDs from appointment to appointment.
Diagnostic-quality images — like CTs, X-rays, and MRI — are stored outside of the EHR, and a limited use of open standards has traditionally held back sharing between health systems.
Care Everywhere uses open image-sharing standards, enabling clinicians to get the image they need to reach a diagnosis faster.
Now, it’s time for TEFCA to use the same standards so that health systems across the U.S can rapidly share diagnostic images.
Mitchell Parker, MD, PhD retweeted
Come learn about the best program ever!!!!! 🎉
🚨Medical students interested in #radonc please join us virtually to meet our amazing residents and learn all about CCF Rad Onc and the upcoming application cycle! We’re so excited to meet you! ☢️🌟
RSVP HERE: bit.ly/4wSwKhd
Mitchell Parker, MD, PhD retweeted
Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE)
sciencedirect.com/science/ar…
